stockrow
Friday 6 November 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
76.08
11.28
+17.41%
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Shares outstanding
CG Oncology, Inc.'s shares outstanding at the end of fiscal 2025 was $77.3M, up 23.7% from $62.5M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $88.9M. CG Oncology, Inc. ranks 176th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $77.3M | 23.69% |
| FY2024 | $62.5M | 1,343.04% |
| FY2023 | $4.3M | 15.77% |
| FY2022 | $3.7M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $88.9M | 0.76% |
| Jun 2026 | $88.2M | 4.36% |
| Mar 2026 | $84.5M | 9.33% |
| Dec 2025 | $77.3M | 0.75% |
| 11 more quarters | Free account |
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IMVT Immunovant, Inc. compare | $205.5M |
| SRRK Scholar Rock Holding Corporation compare | $130.6M |
| CGON CG Oncology, Inc. | $88.2M |
| PTCT PTC Therapeutics, Inc. compare | $83.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | $66.1M |
| KOD Kodiak Sciences Inc. compare | $62.6M |
| MANE Veradermics Incorporated compare | $40.4M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | $40.2M |
| LGND Ligand Pharmaceuticals Incorporated compare | $20.0M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Book value per share
- Revenue growth
- The full statement